Childrens Cancer Group Transplant Trials for Acute Myeloid Leukemia in Children: A Cross-Study Analysis of CCG-251, CCG-213, CCG-2861, and CCG-2891

B. Lange,W. Woods,B. Lampkin,M. Nesbit,S. Feig,R. Wells, J. W. Lee,J. Buckley,D. Hammond

Haematology and Blood Transfusion / Hämatologie und BluttransfusionAcute Leukemias IV（1994）

Cited 0|Views0

No score

Abstract

Since 1978, the Childrens Cancer Group (CCG; see Appendix) has completed three clinical trials in AML in which induction therapy and matched related marrow transplant are major variables [1–7]. A cross-study analysis of the three completed clinical trials, CCG-251, CCG-213 and CCG-2861, helps define the role of induction therapy, allogeneic marrow transplant and chemotherapy in effecting outcome. CCG is currently conducting a fourth trial, CCG-2891, in which autologous transplant is compared to matched related transplant or chemotherapy.

Translated text

Key words

Acute Myeloid Leukemia, Down Syndrome, Induction Therapy, Acute Myeloid Leukemia Patient, Cytosine Arabinoside

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined